한글목차

세계 핵산 의약품 시장의 미래는 유전성 질환, 암, 심혈관 질환 시장에 기회가 있으며, 유망한 것으로 전망되고 있습니다. 세계 핵산 의약품 시장은 2025-2031년 13.7%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 유전성 질환의 유병률 증가, 유전자 수준에서 질병 치료에 대한 수요 증가, 핵산 의약품의 이점에 대한 인식 증가입니다.

• Lucintel의 예측에 따르면, 유형별로는 안티센스 핵산 의약품이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 용도별로는 유전성 질환이 가장 높은 성장이 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.

핵산 의약품 시장의 전략적 성장 기회

기업의 성장을 달성하기 위해, 핵산 의약품의 전망은 주요한 충당금과 함께 몇 가지 전략적 성장 기회를 제공합니다. 이러한 기회를 모색하고 활용하는 것은 해당 기업의 경쟁력 강화에 도움이 될 것입니다.

• 암 치료: mRNA와 유전자 편집 기술의 적용은 새로운 약물을 필요로 하는 새로운 암 치료법을 만들어 환자에게 좋은 결과를 가져다 줄 수 있습니다.
• 희귀 유전질환: 희귀 유전질환은 핵산 치료를 통해 표적으로 삼을 수 있습니다. 결함이 있는 유전자를 직접적으로 보호하거나 복구하는 새로운 유전자 치료법을 개발할 수 있는 능력은 거대한 시장 잠재력을 제시합니다.
• 전염병 백신: 팬데믹 대응을 위한 노력과 다른 전염병에 대한 mRNA 백신의 성공은 이러한 유형의 제품 개발의 시작점이 되었습니다. 이 용도는 공중 보건 백신 대응을 개선하고 백신 제조에 대한 기회를 제공합니다.
• 유전자 치료 플랫폼: 이 분야는 기업 이해관계자들이 유전자 치료 플랫폼에 투자하고 탐색할 가치가 있는 기회입니다. 유전자 치료의 능력은 이 분야를 유리하게 만드는 수많은 질병 치료법을 바꿀 수 있는 잠재력을 가지고 있습니다.
• 개인맞춤형 의료 솔루션: 개인맞춤형 의료를 향한 산업이 발전함에 따라, 핵산 요법을 개발할 수 있는 기회도 찾아올 것으로 보입니다. 이 이점은 유전적으로 표적화된 집단에 시행함으로써 후속 전략의 효율성을 높일 수 있다는 점입니다.

이러한 전략적 성장 분야는 핵산 의약품 시장이 얼마나 큰지 알 수 있습니다. 이러한 변화를 받아들이고 혁신성에 집중하는 기업은 향후 몇 년 동안 성공을 거둘 수 있을 것으로 보입니다.

핵산 의약품 시장 성장 촉진요인 및 과제

핵산 의약품 시장은 사회문화적, 기술적, 경제적, 규제적 요인을 포함한 여러 시장 성장 촉진요인과 도전에 영향을 받고 있습니다. 이러한 역학 속에서 이해관계자들이 이러한 요인을 평가하는 것도 중요합니다.

핵산 의약품 시장을 이끄는 요인은 다음과 같습니다.

• 기술 발전: mRNA 및 유전자 편집과 같은 새로운 핵산 의약품의 지속적인 진화가 시장 확대를 가능하게 하고 있습니다. 이러한 기술은 치료의 임상적 결과를 개선하고 의료진의 수용을 증가시킬 수 있습니다.
• 유전성 질환의 유병률 증가: 유전성 질환과 만성 질환의 유병률 증가는 필요한 치료에 대한 수요를 창출하고 있습니다. 핵산 의약품은 문제 해결에 매우 효과적이기 때문에 시장이 확대되고 있습니다.
• 생명공학 분야 투자: 생명공학, 특히 핵무기 개발에 대한 신흥국 시장의 자금 개척이 이 시장의 성장을 가져오고 있습니다. 벤처캐피털과 정부 보조금은 시장을 파괴하는 프로젝트에 자금을 지원하고 있습니다.
• 규제 지원 블루머: 규제 당국의 이해를 얻음으로써 각 규제 당국이 핵산 의약품 개발에 대해 더 우호적으로 변하고, 더 빠른 승인 절차를 제공하게 되었습니다. 이러한 지원은 새로운 치료법을 출시하는 데 걸리는 시간을 단축시켜 환자에게도 도움이 될 수 있습니다.
• 개인맞춤형 의료에 집중: 개인맞춤형 의료는 환자의 유전자 구성의 차이를 고려한 핵산 치료가 필요합니다. 혁신적인 솔루션의 필요성이 이러한 접근 방식을 강조하고 있습니다.

핵산 의약품 시장의 과제는 다음과 같습니다.

• 규제적 장애물: 규제적 과제: 지지도가 높아지고 있지만, 핵산 의약품에 대한 규제 당국의 승인 획득은 여전히 어려운 과제입니다. 기업들은 규제 준수를 위해 많은 시간과 자원을 투자해야 하며, 이는 제품 개발 과정을 지연시키고 있습니다.
• 높은 개발 비용: 핵산 의약품의 개발 비용이 높아 중소기업의 경쟁력을 제한하고 있습니다. 이 분야에서 성공하기 위해서는 효과적인 자금 조달과 비용 관리가 필수적입니다.
• 대중의 인식과 수용: 핵산 의약품에 대한 회의적인 시각과 잠재적 위험성이 수용을 방해할 수 있습니다. 일반 대중을 교육하고 오해를 해소하는 것이 이러한 치료법에 대한 신뢰를 구축하는 열쇠입니다. 이러한 촉진요인과 과제는 핵산 의약품 시장을 형성하고 성장 추세와 전략적 의사 결정에 영향을 미칩니다. 이해관계자들은 이러한 통찰력을 활용하여 기회를 포착하고 과제를 완화할 수 있습니다.

이러한 촉진요인과 과제는 핵산 의약품 시장의 형태와 특징을 결정하고, 성장 추세와 전략적 선택에 영향을 미칩니다. 다양한 이해관계자들이 이 역동적인 산업에서 어떻게 기회를 얻거나 도전을 완화할 수 있는지, 이러한 역동성을 강조하는 것이 중요합니다.

목차

제1장 주요 요약

제2장 세계의 핵산 의약품 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 핵산 의약품 시장 동향(2019-2024년)과 예측(2025-2031년)
• 유형별 : 세계의 핵산 의약품 시장
  • 안티센스 핵산 의약품
  • siRNA 의약품
  • SaRNA 의약품
  • miRNA 의약품
  • MRNA 의약품
  • 기타
• 용도별 : 세계의 핵산 의약품 시장
  • 유전성 질환
  • 암
  • 심혈관 질환
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 지역별 : 핵산 의약품 시장
• 북미의 핵산 의약품 시장
• 유럽의 핵산 의약품 시장
• 아시아태평양의 핵산 의약품 시장
• 기타 지역의 핵산 의약품 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 유형별 : 세계의 핵산 의약품 시장 성장 기회
  • 용도별 : 세계의 핵산 의약품 시장 성장 기회
  • 지역별 : 세계의 핵산 의약품 시장 성장 기회
• 세계의 핵산 의약품 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 세계의 핵산 의약품 시장 생산능력 확대
  • 세계 핵산 의약품 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 주요 기업 개요

• Sarepta Therapeutics
• Ionis Pharmaceuticals
• Alnylam
• Mina Therapeutics
• BioNTech
• NeXstar Pharmaceuticals
• Nippon Shinyaku

영문목차

The future of the global nucleic acid drug market looks promising with opportunities in the genetic disease, cancer, and cardiovascular disease markets. The global nucleic acid drug market is expected to grow with a CAGR of 13.7% from 2025 to 2031. The major drivers for this market are the growing prevalence of genetic disorders, increasing demand for treating diseases at the genetic level, and rising awareness about the benefits of nucleic acid drugs.

• Lucintel forecasts that, within the type category, antisense nucleic acid drugs are expected to witness the highest growth over the forecast period.
• Within the application category, genetic disease is expected to witness the highest growth.
• In terms of regions, North America is expected to witness the highest growth over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Nucleic Acid Drug Market

The nucleic acid drug market is undergoing dramatic changes with a particular an understanding emerging trends that show why there is a paradigm shift towards more creative and effective therapies. These trends are a product of technological progress, policy improvements, and more intra-industry partnerships.

• Growth of Interest in MRNA Therapies: A great deal of success, was achieved with covid-19 MRNA vaccines, therefore shifting interest in other areas of medicine, such as oncology and rare genetic diseases. The increase in research and investment in mRNA and its technology will enable the rapid creation of customized medications.
• Progress in Gene Editing Technologies: The advent of technologies such as CRISPR and TALEN is changing the scope of nucleic acid drugs since they can edit any component of DNA. Such development will enable the development of precise treatment for genetic disorders leading to safety as well as therapeutic efficacy.
• Regulatory Evolution: Different regulatory authorities around the globe are beginning to cope with the fast pace of growth of many nucleic acid drugs. In parallel, new policies and expedited regulatory pathways are being developed to advance the speedy transformation and marketing of new innovative drugs.
• Collaborative Research Efforts: Cooperation among universities, biotech companies, and legacy pharmaceutical firms is productive to the creation of nucleic acid medicines. Collaboration is helpful in information dissemination, resource mobilization, and enhancing the speed of the clinical trial phase.
• Focus on Personalized Medicine Policy: The strategy of personalized medicine is increasingly becoming relevant in the nucleic acid market. This focused therapy works well to minimize side effects and improves the therapeutic benefits, making it a step forward.

These trends are proving to be game changers in the nucleic acid drug market, giving rise to new modalities that are making patients' lives better. The stakeholders need to be agile in order to take the most out of these trends.

Recent Developments in the Nucleic Acid Drug Market

The nucleic acid drug market has been undergoing dramatic changes on account of technological developments and more funding. Other interesting advancements tend towards the development of more RNA-targeted drugs and gene therapy.

• Increased Use of mRNA Therapeutics: The successful use of mRNA vaccines during the COVID-19 pandemic has created great interest in mRNA therapeutics. Now companies are investigating the use of mRNA technologies for cancer immunotherapy and treatment of other diseases like rare genetic disorders, thus broadening the scope of therapy.
• Gene Editing Technologies: The current advancement in gene editing tools and technologies that include CRISPR has made it possible to formulate new strategies for targeted therapy. These improvements allow efficient alterations of genes and have the possibility to address genetic disorders while building a future in cancer treatment.
• Strategy in Biotech Startup Investments: The venture capital investment activity in biotech startups, technology that develops nucleic acid drugs, has undergone a boost. Investments of these types make possible emerging technologies, which in particular speed up the processes of bringing new treatments to the market, developing the ecosystem of research and development.
• Global Partnerships: Partnership projects between countries or institutions are more common in the field of nucleic acid drug development. These working groups enhance the sharing of resources and resources and consequently combustion the research leading to faster development of new therapies to treat diseases.
• Regulatory Reforms: The level agencies are constantly making efforts in order to improve and fast-track the approval of nucleic acid drugs. This entails introducing changes and reforms in the design of such products as unusual therapy which enable the fast offering of such therapy to those patients who need it.

New changes have emerged mostly in the nucleic acid drug market that has accelerated growth through stimulating creativeness in the areas of therapies provision. Additionally, collaboration and supporting developments through regulation will be important for the further advancement of this industry.

Strategic Growth Opportunities for Nucleic Acid Drug Market

To achieve corporate growth, the nucleic acid drug outlook offers a few strategic growth opportunities along with major appropriations. Seeking and exploiting these opportunities seem competitive enhancing capability to the firms concerned.

• Cancer Treatment: Nucleic acid drugs become another key factor for market expansion in oncology. m Applications of mRNA and gene editing technologies are utilized in the creation of novel cancer therapy, which areas require new medicines, and bring better results for patients.
• Rare Genetic Disorders: Rare genetic disorders can be targeted through nucleic acid therapies. The ability to come up with novel gene therapy that directly protects or repairs defective genes presents a huge market potential.
• Infectious Disease Vaccines: The pandemic response efforts, along with the success of mRNA vaccines for other infectious diseases, became a gateway for the creation of this type of product. This application can improve the public health vaccine response and also provide appetizing opportunities in vaccine manufacture.
• Gene Therapy Platforms: This is an opportunity area worth exploring and making investments by company stakeholders in the gene therapy platforms. The capacity to administer gene therapies can change the numerous disease treatment practices making this area lucrative.
• Personalized Medicine Solutions: As the industry advances towards personalized medicine, opportunities to develop nucleic acid therapies will also be presented. The benefits of this are enhancing the efficiency of subsequent strategies by implementing them on genetically targeted populations.

These strategic growth areas can show how big the market is for nucleic tool drugs. Firms that embrace these changes and concentrate on innovativeness will be prepared for success in the coming years.

Nucleic Acid Drug Market Driver and Challenges

The nucleic acid drug market is influenced by several drivers and challenges which include sociocultural, technological, economic, and regulatory factors. It is also important to appreciate these factors in order for stakeholders to maneuver in such dynamics.

The factors responsible for driving the nucleic acid drug market include:

• Technological Advancements: Continued evolution of novel nucleic acid drugs such as mRNA and gene editing makes expansion of the market possible. These technologies improve the clinical outcomes of the therapies which increase the uptake of healthcare providers.
• Rising Prevalence of Genetic Disorders: The rising prevalence of genetic disorders and chronic diseases is creating a demand for necessary therapies. Nucleic acid drugs are very effective in solving challenges, hence growing the market.
• Investment in Biotech Sector: Increasing funds in biotechnology, particularly for its nuclear arms development is leading to growth in this market. Venture capital and government grants are funding the projects that are going to be disruptive in the market.
• Regulatory Support Blumer: Availing understanding, each of such regulatory agencies has become more friendly to nucleic acid Drug development and provides quicker approval processes. This support decreases the time new therapies take to go to market and that is beneficial to the patients.
• Focus on Personalized Medicine: Personalized medicine requires nucleic acid therapies that take in account the differences in the genetic composition of patients. The need for innovative solutions stresses this approach.

Challenges in the nucleic acid drug market are:

• Regulatory Hurdles: Despite increasing support, navigating regulatory approval for nucleic acid drugs remains a challenge. Companies must invest significant time and resources to meet compliance, slowing the product development process.
• High Development Costs: The cost of developing nucleic acid drugs is high, limiting the ability of smaller firms to compete. Effective funding and cost management are critical to success in this field.
• Public Perception and Acceptance: Public skepticism about nucleic acid medicines and the potential risks involved may hinder acceptance. Educating the public and addressing misconceptions is key to building confidence in these therapies. These drivers and challenges shape the nucleic acid drug market, influencing growth trends and strategic decisions. Stakeholders can use these insights to identify opportunities and mitigate challenges.

These drivers and challenges equally determine the shape and characteristics of nucleic acids drugs market and dictate its growth trends, as well as strategic choices. It is important to emphasize these dynamics because of how various stakeholders can gain opportunities and/or mitigate challenges in this dynamic industry.

List of Nucleic Acid Drug Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies nucleic acid drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the nucleic acid drug companies profiled in this report include-

• Sarepta Therapeutics
• Ionis Pharmaceuticals
• Alnylam
• Mina Therapeutics
• BioNTech
• NeXstar Pharmaceuticals
• Nippon Shinyaku

Nucleic Acid Drug by Segment

The study includes a forecast for the global nucleic acid drug market by type, application, and region.

Nucleic Acid Drug Market by Type [Analysis by Value from 2019 to 2031]:

• Antisense Nucleic Acid Drugs
• SiRNA Drugs
• SaRNA Drugs
• MiRNA Drugs
• MRNA Drugs
• Others

Nucleic Acid Drug Market by Application [Analysis by Value from 2019 to 2031]:

• Genetic Disease
• Cancer
• Cardiovascular Diseases
• Others

Nucleic Acid Drug Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Nucleic Acid Drug Market

The expansion of the nucleic acid drug market is moving quickly, and it is particularly boosted due to the new entries in RNA therapies as well as gene editing technologies. Thanks to continuous advancements in understanding the many genetic diseases, there is increasing demand for specific therapies that have caused a lot of investment and research activity worldwide. Countries like the U.S., China, Germany, India, and Japan are some of the countries that are making strides in these potentials, each in a different manner with its level of enhancement of the nucleic acid drug arena.

• United States: In the U.S., the nucleic acid drug market is booming with efficient focus on mRNA therapeutic drugs owing to the recent success of COVID-19 vaccination marketing. The leading biotech companies are actively working on mRNA-oriented drug pipelines for multiple disease applications including but not limited to cancers and inherited disorders. The FDA maintains an encouraging environment for the advancement of new technologies by assisting in the fast-tracking of new technology drugs to the market through an accelerated review. pharmaceutical industry collaborations with universities are becoming more accustomed and prevalent leading to better developments in CRISPR and other forms of gene editing technologies.
• China: The market for nucleic acid drugs in China is advancing rapidly thanks to the government's keenness to enhance biotechnology research and development. The country has attracted tremendous investment in mRNA technology, where several local players are manufacturing vaccines and therapeutics. Efforts are being made to create a legal framework that allows for an easy and fast regulatory approval for nucleic acid drugs which in turn makes them available in the market quickly. Moreover, partnerships with foreign companies are stimulating know-how and technological development, making China a significant player in the nucleoside drugs market.
• Germany: Germany has been labeled a strong biotechnology country with an emerging nucleic acid drug market. With the focus shifting towards RNA therapeutics and gene editing technologies, the state has several ongoing clinical trials for gene therapy medicine under development. There is a growing tendency in German enterprises to sign more research collaborations to expedite nucleic acid drug development. The attitude to new attachments is positive, and the approval process of new therapeutics is framed which creates further opportunities for Germany in this respect.
• India: The nucleic acid drug market in India is gradually evolving, particularly in areas like mRNA technology and gene therapies. There are government efforts towards biotechnology research and some young companies work on nucleic acid drugs. There are increasing partnerships between Indian companies and foreign pharmaceutical corporations which help in technological and innovative development. However, such challenges are present as obtaining regulatory clearances and the shortage of specialists devoted to the nucleic acid drugs development sphere are on the way.
• Japan: The nucleic acid drug market in Japan is defined by the high expenditure on genetic therapies along with a clear regulatory environment. The country is emerging into the creation of mRNA vaccines, developing gene modification techniques and leading pharmaceutical companies are researching them. In this light, the last few years saw a rise in academic-corporate collaborations aimed at supporting invention, while the Japanese government initiated reforms intended for the development of biotechnology. As new technologies develop and those barriers are cleared the market will grow by leaps and bounds in addressing the unmet medical needs in genetics diseases and oncology.

Features of the Global Nucleic Acid Drug Market

Market Size Estimates: Nucleic acid drug market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Nucleic acid drug market size by type, application, and region in terms of value ($B).

Regional Analysis: Nucleic acid drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the nucleic acid drug market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the nucleic acid drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the nucleic acid drug market by type (antisense nucleic acid drugs, SiRNA drugs, SaRNA drugs, MiRNA drugs, MRNA drugs, and others), application (genetic disease, cancer, cardiovascular diseases, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Nucleic Acid Drug Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Nucleic Acid Drug Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Nucleic Acid Drug Market by Type
  • 3.3.1: Antisense Nucleic Acid Drugs
  • 3.3.2: SiRNA Drugs
  • 3.3.3: SaRNA Drugs
  • 3.3.4: MiRNA Drugs
  • 3.3.5: MRNA Drugs
  • 3.3.6: Others
• 3.4: Global Nucleic Acid Drug Market by Application
  • 3.4.1: Genetic Disease
  • 3.4.2: Cancer
  • 3.4.3: Cardiovascular Diseases
  • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Nucleic Acid Drug Market by Region
• 4.2: North American Nucleic Acid Drug Market
  • 4.2.1: North American Market by Type: Antisense Nucleic Acid Drugs, SiRNA Drugs, SaRNA Drugs, MiRNA Drugs, MRNA Drugs, and Others
  • 4.2.2: North American Market by Application: Genetic Disease, Cancer, Cardiovascular Diseases, and Others
• 4.3: European Nucleic Acid Drug Market
  • 4.3.1: European Market by Type: Antisense Nucleic Acid Drugs, SiRNA Drugs, SaRNA Drugs, MiRNA Drugs, MRNA Drugs, and Others
  • 4.3.2: European Market by Application: Genetic Disease, Cancer, Cardiovascular Diseases, and Others
• 4.4: APAC Nucleic Acid Drug Market
  • 4.4.1: APAC Market by Type: Antisense Nucleic Acid Drugs, SiRNA Drugs, SaRNA Drugs, MiRNA Drugs, MRNA Drugs, and Others
  • 4.4.2: APAC Market by Application: Genetic Disease, Cancer, Cardiovascular Diseases, and Others
• 4.5: ROW Nucleic Acid Drug Market
  • 4.5.1: ROW Market by Type: Antisense Nucleic Acid Drugs, SiRNA Drugs, SaRNA Drugs, MiRNA Drugs, MRNA Drugs, and Others
  • 4.5.2: ROW Market by Application: Genetic Disease, Cancer, Cardiovascular Diseases, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Nucleic Acid Drug Market by Type
  • 6.1.2: Growth Opportunities for the Global Nucleic Acid Drug Market by Application
  • 6.1.3: Growth Opportunities for the Global Nucleic Acid Drug Market by Region
• 6.2: Emerging Trends in the Global Nucleic Acid Drug Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Nucleic Acid Drug Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Nucleic Acid Drug Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Sarepta Therapeutics
• 7.2: Ionis Pharmaceuticals
• 7.3: Alnylam
• 7.4: Mina Therapeutics
• 7.5: BioNTech
• 7.6: NeXstar Pharmaceuticals
• 7.7: Nippon Shinyaku